Literature DB >> 24269090

Erythrocytes' antioxidative capacity as a potential marker of oxidative stress intensity in neuroinflammation.

Srdjan Ljubisavljevic1, Ivana Stojanovic2, Tatjana Cvetkovic2, Slobodan Vojinovic3, Dragan Stojanov4, Dijana Stojanovic5, Nikola Stefanovic6, Dusica Pavlovic2.   

Abstract

The study is designed to assess the oxidative stress intensity in erythrocytes obtained from patients in different clinical phenotypes of neuroinflammation, defined as clinically isolated syndrome (CIS) and relapsing-remitting multiple sclerosis (RRMS). Advanced oxidation protein products (AOPP), malondialdehyde (MDA) and superoxide dismutase (SOD) activity were measured and compared with patients' clinical severity (expanded disability status scale-EDSS), radiological findings (gadolinium enhancement lesion volume-Gd+) and disease duration (DD). AOPP, MDA values and SOD activity were significantly higher in both study patients than in the control group (p < 0.05). While AOPP and MDA approached higher values in RRMS, compared to the CIS group (p > 0.05, p < 0.05, respectively), SOD activity showed higher values in CIS than in RRMS patients (p < 0.05). Both study patients with higher EDSS, higher number of total radiological lesions and longer DD, had higher AOPP and MDA content (p < 0.05, p > 0.05). SOD activity was lower in both study patients with higher EDSS, higher number of total radiological lesions and longer DD (p < 0.05, p > 0.05). There were positive correlations between AOPP and DD and EDSS in CIS patients (p < 0.01), and MDA levels and DD, EDSS and Gd+ in CIS, as well as with EDSS in RRMS patients (p < 0.01). There were negative correlations between SOD activity and DD and EDSS in both study patients (p < 0.01), as well as, between SOD activity and Gd+ in CIS patients (p < 0.01). The measured erythrocytes' biomarkers might represent one of the important biomarkers for the evaluation of the oxidative status of neuroinflammation and disease severity, especially in its early phase, defined as CIS.
Copyright © 2013 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Advanced oxidation protein products; Clinically isolated syndrome; Malondialdehyde; Relapsing–remitting multiple sclerosis; Superoxide dismutase

Mesh:

Substances:

Year:  2013        PMID: 24269090     DOI: 10.1016/j.jns.2013.11.006

Source DB:  PubMed          Journal:  J Neurol Sci        ISSN: 0022-510X            Impact factor:   3.181


  10 in total

1.  Clinical relevance of circadian melatonin release in relapsing-remitting multiple sclerosis.

Authors:  Simone Kern; Michael Geiger; Madlen Paucke; Alina Kästner; Katja Akgün; Tjalf Ziemssen
Journal:  J Mol Med (Berl)       Date:  2019-08-30       Impact factor: 4.599

2.  Immune-Inflammatory and Oxidative and Nitrosative Stress Biomarkers of Depression Symptoms in Subjects with Multiple Sclerosis: Increased Peripheral Inflammation but Less Acute Neuroinflammation.

Authors:  Ana Paula Kallaur; Josiane Lopes; Sayonara Rangel Oliveira; Andrea Name Colado Simão; Edna Maria Vissoci Reiche; Elaine Regina Delicato de Almeida; Helena Kaminami Morimoto; Wildea Lice Carvalho Jennings de Pereira; Daniele Frizon Alfieri; Sueli Donizete Borelli; Domacio Ramon Kaimen-Maciel; Michael Maes
Journal:  Mol Neurobiol       Date:  2015-09-24       Impact factor: 5.590

3.  Evaluation of Delta-Aminolevulinic Dehydratase Activity, Oxidative Stress Biomarkers, and Vitamin D Levels in Patients with Multiple Sclerosis.

Authors:  Carla Roberta Nunes Polachini; Roselia Maria Spanevello; Daniela Zanini; Jucimara Baldissarelli; Luciane Belmonte Pereira; Maria Rosa Chitolina Schetinger; Ivana Beatrice Mânica da Cruz; Charles Elias Assmann; Margarete Dulce Bagatini; Vera Maria Morsch
Journal:  Neurotox Res       Date:  2015-12-21       Impact factor: 3.911

4.  Advanced Oxidative Protein Products Role in Multiple Sclerosis: a Systematic Review and Meta-analysis.

Authors:  Patrícia Rodrigues; Guilherme Vargas Bochi; Gabriela Trevisan
Journal:  Mol Neurobiol       Date:  2021-08-15       Impact factor: 5.590

Review 5.  Central pathways causing fatigue in neuro-inflammatory and autoimmune illnesses.

Authors:  Gerwyn Morris; Michael Berk; Ken Walder; Michael Maes
Journal:  BMC Med       Date:  2015-02-06       Impact factor: 8.775

Review 6.  New Insights into the Role of Oxidative Stress Mechanisms in the Pathophysiology and Treatment of Multiple Sclerosis.

Authors:  Bożena Adamczyk; Monika Adamczyk-Sowa
Journal:  Oxid Med Cell Longev       Date:  2016-10-18       Impact factor: 6.543

Review 7.  Erythrocytes in multiple sclerosis - forgotten contributors to the pathophysiology?

Authors:  Kira Groen; Vicki E Maltby; Katherine A Sanders; Rodney J Scott; Lotti Tajouri; Jeannette Lechner-Scott
Journal:  Mult Scler J Exp Transl Clin       Date:  2016-05-19

8.  Redox Imbalance in CD4+ T Cells of Relapsing-Remitting Multiple Sclerosis Patients.

Authors:  Mohammad Javad Tavassolifar; Abdorreza Naser Moghadasi; Behnaz Esmaeili; Omid Sadatpour; Mohammad Vodjgani; Maryam Izad
Journal:  Oxid Med Cell Longev       Date:  2020-12-02       Impact factor: 6.543

9.  Antioxidant and Anti-inflammatory Diagnostic Biomarkers in Multiple Sclerosis: A Machine Learning Study.

Authors:  Leda Mezzaroba; Andrea Name Colado Simão; Sayonara Rangel Oliveira; Tamires Flauzino; Daniela Frizon Alfieri; Wildea Lice de Carvalho Jennings Pereira; Ana Paula Kallaur; Marcell Alysson Batisti Lozovoy; Damacio Ramón Kaimen-Maciel; Michael Maes; Edna Maria Vissoci Reiche
Journal:  Mol Neurobiol       Date:  2020-01-22       Impact factor: 5.590

10.  Decreased Cerebrospinal Fluid Antioxidative Capacity Is Related to Disease Severity and Progression in Early Multiple Sclerosis.

Authors:  Margarete M Voortman; Anna Damulina; Lukas Pirpamer; Daniela Pinter; Alexander Pichler; Christian Enzinger; Stefan Ropele; Gerhard Bachmaier; Juan-Jose Archelos; Gunther Marsche; Michael Khalil
Journal:  Biomolecules       Date:  2021-08-25
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.